2 results
Approved WMOCompleted
First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measured by change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotide modifies…
Approved WMOCompleted
1. To describe mitoPO2 in clinically admitted critically ill septic patients receiving fluid therapy (consisting of crystalloid, albumin and/or red cell transfusion).2. To describe the effects of fluid therapy on mitoPO2 and on other physiological…